Update shared on08 Aug 2025
Fair value Decreased 1.06%With OssDsign's consensus price target revised lower, primarily driven by a notable drop in its Future P/E from 77.22x to 64.47x, the fair value estimate has decreased from SEK15.67 to SEK14.83.
What's in the News
- An undisclosed buyer acquired an unknown minority stake in OssDsign AB from Karolinska Development AB.
- One-year PROPEL registry results for OssDsign Catalyst showed an 88.4% spinal fusion rate in a highly complex patient cohort, with no unexpected device-related adverse events and significant patient improvement.
- Completed a follow-on equity offering of SEK 158.125 million via direct listing at SEK 13.75 per share.
- Revised financial targets to achieve over SEK 400 million in sales by 2028 (30%+ CAGR), with expected EBIT profitability in the second half of the 2025–2028 strategy period.
- Surpassed 10,000 patients treated with OssDsign Catalyst in the US, signaling market traction for the nanosynthetic bone graft.
Valuation Changes
Summary of Valuation Changes for OssDsign
- The Consensus Analyst Price Target has fallen from SEK15.67 to SEK14.83.
- The Future P/E for OssDsign has significantly fallen from 77.22x to 64.47x.
- The Discount Rate for OssDsign remained effectively unchanged, at 5.54%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.